Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Concord Biotech Limited Call Transcript 2025

Jan 31, 2025

61064_rns_2025-01-31_da489ba6-6ad4-4b58-b65d-78fa61ffc766.pdf

Call Transcript

Open in viewer

Opens in your device viewer

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: [email protected]

-------------------------------------------------------------------------------------------------------------------------------------------- January 31, 2025

ToThe Manager, Listng DepartmentNatonal Stock Exchange of India Ltd.Plot No. C/1 G Block,Bandra-Kurla Complex, Bandra (East),Mumbai -400 051Symbol: CONCORDBIO ToGeneral Manager, Listng DepartmentBSE LimitedPhiroze Jeejabhoy Towers,Dalal Street,Mumbai – 400 001ScripCode: 543960

Dear Sir/Ma’am,

Subject: Earnings Call Invite for the operatonal and fnancial performance of the Company for the Third Quarter and Nine months ended 31[st] December, 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended 31[st] December, 2024, scheduled on Friday, 14[th] February, 2025 at 04:00 P.M. IST. The Earnings Call invite is enclosed for your records.

The conference/Earning Call Invitation is enclosed herewith.

Kindly take the same into your records and oblige.

Thanking you, Yours faithfully

For Concord Biotech Limited

Digitally signed by PRAKASH PRAKASH LALCHAND SAJNANI LALCHAND SAJNANI Date: 2025.01.31 14:48:24 +05'30'

Prakash Sajnani Company Secretary and Compliance Officer M. No. F6242 Encl: As above

-----------------------------------------------------------------------------------------------------------------------------------------Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com

JM Financial Institutional Securities invites you to the

==> picture [106 x 25] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

----- Start of picture text ----- CORPORATE ACCESS----- End of picture text -----

==> picture [142 x 40] intentionally omitted <==

3QFY25 earnings conference call with

Concord Biotech Limited

on Friday, 14 February 2025

4:00 PM IST | 05:30 AM USA EST | 10:30 AM UK TIME | 06:30 PM HK/SINGAPORE TIME

Company Participants

Mr. Sudhir Vaid

Chairman & Managing Director

Mr. Lalit Sethi

Chief Financial Officer

Mr. Ankur Vaid

Joint Managing Director And Chief Executive Officer

Mr. Prakash Sajnani

Compliance Officer And Assistant Vice President, Accounts

Universal Dial-in:

+91-22-6280 1366 | +91-22-7115 8267

Toll Free Number – International USA: UK: Singapore: Hong Kong: 1 866 746 2133 0 808 101 1573 800 101 2045 800 964 448

Please dial-in 10 minutes prior to the conference schedule to ensure that you are connected in time

Diamond Pass Link:

==> picture [187 x 34] intentionally omitted <==

For further information, please contact

Mr. Amey Chalke | +91-22-6630 3056 | [email protected] Mr. Raghav Vedanarayanan | +91-22-6224 1851 | [email protected] Ms. Lorraine Gomes | +91-22-6630 3076 | [email protected]

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610 Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India. Board: +9122 6630 3030 | Fax: +91 22 6630 3488 | Email: [email protected] | www.jmfl.com Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: [email protected] Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: [email protected]

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Safe harbor:

The proposed management discussion and comments thereof may include forward-looking statements. Forward-looking statements are statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact. All forward looking statements are subject to risks, uncertainties and assumptions that could cause actual results of operations and financial conditions to differ materially from those contemplated by the relevant statement. All Conference Call Participants should not place undue reliance on these forward-looking statements. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities Limited or provide any assurance of returns to investors.